Diagnostic reagents company Immuno Concepts said on Wednesday that it has passed the Histofluor Rodent LKS Rodent Tissue Slides for manual and Image Navigator use through the US Food and Drug Administration's (FDA) 510(k) process.
Following the US FDA's clearance, Histofluor Rodent Tissue Slides are available in both mouse and rat substrates and can be read manually or scanned using the innovative Image Navigator automated microscope, added the company.
The company stated the indirect immunofluorescent (IIF) test has long been the preferred method for determination of Anti-Mitochondrial Antibodies (AMA), Anti-Smooth Muscle Antibodies (ASMA) and Anti-Parietal Cell Antibodies. These autoantibodies are associated with several autoimmune diseases, including Pernicious Anemia or Autoimmune Gastritis, Primary Biliary Cholangitis (PBC) and Autoimmune Hepatitis.
According to the company, the same slides and reagents for the Histofluor Rodent Tissue Slides are used regardless of whether the slides are read manually or scanned on the Image Navigator.
In conjunction, the previously US FDA-Cleared Image Navigator eliminates the usual tedious labor of the IIF test, while still allowing the laboratory professional to control the interpretation and reporting of these tests, concluded the company.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca